Kristie L. Kahl

A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

Among 2 patient subgroups with advanced, HER2-mutant non–small cell lung cancer, sevabertinib showed comparable objective response rates.

No fatalities were observed with fruquintinib plus camrelizumab, paclitaxel liposome, and nedaplatin when treating esophageal squamous cell carcinoma.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.

The ALASCCA trial found that the risk of disease recurrence was reduced by 51% for patients with PIK3CA-mutated colorectal cancer who took aspirin for 3 years.

Acalabrutinib-based treatment also improves overall survival vs standard chemoimmunotherapy in the phase 3 AMPLIFY trial.

PFS and OS were significantly improved with subcutaneous daratumumab vs active monitoring in patients with smoldering multiple myeloma.

Daratumumab plus VRd showed a deepened MRD and PFS rate for patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma.

For patients with relapsed or refractory KMT2Ar acute leukemia, revumenib showed promising outcomes of overall response rate and duration of response.

CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for surrounding the multidisciplinary approach at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.

“When thinking about treatment options for refractory DLBCL you consider: Is it safe to give an older patient CAR T-[cell therapy]?,” said Jennifer Amengual, MD.

CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, to highlight what to expect in the latest oncology developments from the 42nd Annual Chemotherapy Foundation Symposium to be held in New York City.

The phase 3 CAPItello-290 trial of capivasertib plus paclitaxel did not meet its primary end point of improved overall survival in the frontline setting of metastatic triple-negative breast cancer.

CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for surrounding the multidisciplinary approach at the upcoming ESMO Congress in Barcelona, with some additional tidbits to round out the main event.

Phase 2 data support further evaluation of datopotamab deruxtecan in patients with non–small cell lung cancer and brain metastases.

The addition of tucidinostat to R-CHOP demonstrated promising safety and efficacy outcomes in patients with previously untreated diffuse large B-cell lymphoma) expressing MYC and BCL-2, according to interim analysis results.

A PFS benefit with adagrasib was observed across all key patient subgroups in the phase 3 KRYSTAL-12 trial.

Additional research may be necessary to validate the efficacy of telehealth interventions in clinical activities for patients with cancer.

Lack of energy, difficulty with sleeping, and pain were some of the most common symptoms reported in older patients with cancer.

Roshni Rao, MD, FACS, discussed the use of neoadjuvant chemoimmunotherapy and its complications in the treatment of patients with triple-negative breast cancer.

In clinically node-positive breast cancer, clipping of lymph nodes may induce higher rates of sentinel lymph node surgery after neoadjuvant chemotherapy.

Those aged 18 to 40 years with invasive, HER2-positive breast cancer showed a survival benefit from upfront surgery over neoadjuvant chemotherapy.

Data from the GETUG-AFU 18 trial support high-dose radiation plus long-term androgen deprivation therapy as a standard of care in high-risk prostate cancer.

Duration of response results with pembrolizumab plus lenvatinib in advanced hepatocellular carcinoma appear to be ‘promising’ in the phase 3 LEAP-002 trial.

Because patients with myeloma are at a high risk for financial hardship, study findings support the use of a financial navigation program to reduce financial toxicities of patients.

Zanubrutinib plus obinutuzumab and venetoclax appears to be well tolerated in patients with TP53-mutated mantle cell lymphoma, says Anita Kumar, MD.

Acalabrutinib on its own or in combination with obinutuzumab increases PFS and ORR in patients with chronic lymphocytic leukemia regardless of mutation status, according to follow-up data from the ELEVATE-TN trial.

Single-agent treatment with odronextamab continued to demonstrate encouraging clinical activity, along with a manageable safety profile, in patients with relapsed/refractory diffuse large B-cell lymphoma.

Treatment with zanubrutinib also appears to improve overall survival compared with ibrutinib among patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in the phase 3 ALPINE trial.